Skip to main content
. 2022 Nov 10;2(11):1404–1417. doi: 10.1158/2767-9764.CRC-22-0266

FIGURE 5.

FIGURE 5

ZL-1201 combines with SoC therapeutics and increased efficacy in vivo. Antitumor activities of isotype control, ZL-1201, herceptin, docetaxel (DTX; A and C) or paclitaxel (PTX; B), or their combinations as indicated on HCC1954 (A), SKOV3 (B) breast cancer xenograft models, and on ST-02-0077 gastric PDX model (C). D, Antitumor activities of isotype control, ZL-1201, erbitux, cisplatin, or their combinations as shown in FaDu HNSCC xenograft model. E, Antitumor activities of isotype control, ZL-1201, rituximab, or their combinations as indicated in Raji lymphoma cancer xenograft model. Tumor sizes were measured twice per week and tumor growth curves were shown as mean + SEM. *, P < 0.05; **, P < 0.01.